What’s New


Jan 8, 2024

Alimentiv Announces Pierre Gaudreault as New Chief Executive Officer

London, Ontario, Canada, January 8, 2024 – Alimentiv Inc. (“Alimentiv”) is pleased to announce the appointment of Pierre Gaudreault as its Chief Executive Officer, effective January 2024. Th…


Nov 8, 2023

Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials.

LONDON, ON, November 8, 2023 – Alimentiv Inc., AcelaBio Inc., and PharmaNest Inc. are pleased to announce their collaborative effort aimed at revolutionizing precision medicine and artificial in…


Sep 13, 2022

Discovery Accelerated: Clinical Trials in Pediatric IBD


Aug 17, 2022

Alimentiv Health Trust announces the appointment of New Board Members to the Alimentiv Holdings Board of Directors 

London, ON, CANADA, Release: August 18, 2022 Alimentiv Health Trust is pleased to announce the appointment of Dr. Amara Siva, Mr. John Fox and Mr. Paul Rothwell to the Alimentiv Holdings Board of…


Jul 16, 2022

Heterogeneity in Efficacy and Safety Endpoints for Pediatric Clinical Trials in Inflammatory Bowel Disease: A Need for Harmonization

Eileen Crowley, Vipul Jairath.


Jul 14, 2022

Employee Spotlight – Jill Klein

At Alimentiv, our employees come first. We engage inspired and talented individuals who are motivated by our mission and vision, and we continue to learn more about our employees and their unique and …


Jul 3, 2022

Placebo rates in randomized controlled trials of proctitis therapy: A systematic review and meta-analysis

Christopher Ma, Rocio Sedano, Vipul Jairath.


Jun 24, 2022

Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn’s Disease: Meta-Analysis of Randomised Controlled Trials

Brian Feagan, Christopher Ma, Claire E Parker, Eileen Crowley, Geert D’Haens, Guangyong Zou, Malcolm Hogan, Rocio Sedano, Vipul Jairath.